Medicago And GSK Announce Positive Phase 3 Efficacy And Safety Results For Adjuvanted Plant-Based COVID-19 Vaccine Candidate; Says Primary And Secondary Endpoints For Which Data Are Available Were Met, 75.3% Efficacy